文献速递前列腺癌

根治性前列腺切除术后单标志物免疫组化与商业基因表达谱的预后效用比较

Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
PubMed 文献 · Eur Urol · 2018-09-01

该研究纳入424例接受根治性前列腺切除术的局限性前列腺癌患者,比较PTEN、Ki-67和ERG免疫组化与基于31基因的细胞周期进展(CCP)评分的预后效用。结果显示,校正CAPRA-S后,PTEN状态与CCP评分对转移或前列腺癌特异性死亡的区分度相似(c-index 0.80 vs 0.81)。

要点

  • PTEN状态与商业CCP评分对转移或PCSM的区分度相近(c-index 0.80 vs 0.81)。
  • CCP评分与复发风险(HR 1.51)及转移/PCSM风险(HR 2.15)相关。
  • PTEN缺失与转移/PCSM风险相关(HR 5.26),但与复发无关。

核心结论

  • PTEN状态对转移或前列腺癌死亡的区分度与商业RNA扩增CCP检测相当。

研究设计与样本

  • 研究纳入424例接受根治性前列腺切除术的局限性前列腺癌患者,中位年龄59岁,中位随访114个月。
  • 采用组织微阵列进行PTEN、Ki-67和ERG免疫组化分析,并与基于31基因归一化至15个管家基因的CCP评分比较。

主要发现

  • 术后10年,27%患者出现生化复发,4%发生转移或前列腺癌特异性死亡。
  • 校正CAPRA-S后,CCP与复发风险(HR 1.51,95%CI 1.08-2.11)及转移/PCSM风险(HR 2.15,95%CI 1.36-3.39)相关。
  • 校正CAPRA-S后,PTEN缺失与转移/PCSM风险相关(HR 5.26,95%CI 2.57-10.7),但与复发无关。
  • PTEN状态联合CAPRA-S的c-index(0.80)与CCP联合CAPRA-S(0.81)对转移/PCSM风险的区分度相似。
  • 整合Ki-67和ERG状态未较CAPRA-S联合PTEN alone改善c-index。

关键数值与推荐

  • PTEN状态联合CAPRA-S对转移/PCSM风险的c-index为0.80。
  • CCP联合CAPRA-S对转移/PCSM风险的c-index为0.81。

临床怎么用

  • 在临床信息基础上,PTEN状态可替代商业多基因检测用于预测转移或死亡风险。
  • 降低前列腺癌预后工具成本可能有助于扩大可及性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the availability of numerous genomic predictors of prostate cancer (PCa) outcome, few comparative studies have been performed. OBJECTIVE: To compare the prognostic utility of previously validated immunohistochemical (IHC) markers with an expression-based cell-cycle progression (CCP) score. DESIGN, SETTING, AND PARTICIPANTS: We identified 424 men with localized PCa treated with radical prostatectomy (RP). IHC analysis was performed using a tissue microarray to examine the expression status of PTEN, Ki-67, and ERG compared with previously calculated CCP scores derived from 31 genes normalized to 15 housekeeper genes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Associations of IHC status and CCP scores, adjusted for clinical and pathologic characteristics were performed using Cox regression and competing risks regression to examine risk of biochemical recurrence (BCR), and metastasis or PCa-specific mortality (PCSM). We compared models using concordance index (c-index) testing. INTERVENTION: RP. RESULTS AND LIMITATIONS: Median age at treatment was 59 yr, and patients were followed for a median of 114 mo after RP. By 10 yr after RP, 27% experienced BCR and 4% developed metastasis or PCSM. In a multivariable model adjusted for Cancer of the Prostate Risk Assessment score (CAPRA-S), CCP was associated with risks of recurrence (hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.08-2.11) and metastasis/PCSM (HR 2.15, 95% CI 1.36-3.39). PTEN loss was not associated with recurrence but was associated with metastasis/PCSM (HR 5.26, 95% CI 2.57-10.7), adjusted for CAPRA-S. The c-index for models consisting of PTEN status and CAPRA-S was similar (0.80) for risk of metastasis/PCSM when compared with CCP and CAPRA-S (0.81). Integration of Ki-67 and ERG status did not improve the c-index relative to CAPRA-S and PTEN alone. CONCLUSIONS: PTEN status offered comparable discrimination of the risk of metastasis or death from PCa relative to a commercial RNA amplification-based CCP assay. Efforts are warranted to reduce the cost of PCa prognostic tools in order to expand access. PATIENT SUMMARY: We compared a commercial genomic signature and the expression status of single genes to predict outcomes in men with prostate cancer who were treated with surgical removal. When accounting for clinical information about the patient's cancer, the status of the PTEN gene alone matched a multigene panel to predict which patient's cancer would metastasize or lead to death from the disease.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Leapman MS, Nguyen HG, Cowan JE, et al. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. Eur Urol. 2018. PMID: 30181067. doi:10.1016/j.eururo.2018.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。